DNLI
Denali Therapeutics Inc

1,827
Mkt Cap
$2.83B
Volume
1.13M
52W High
$24.35
52W Low
$10.57
PE Ratio
-6.28
DNLI Fundamentals
Price
$18.27
Prev Close
$18.11
Open
$18.09
50D MA
$17.37
Beta
1.58
Avg. Volume
1.68M
EPS (Annual)
-$2.57
P/B
2.89
Rev/Employee
$0.00
News
all
press releases
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
Zacks·8d ago
News Placeholder
More News
News Placeholder
3 Biotech Stocks With Major 2026 Catalysts
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
Zacks·17d ago
News Placeholder
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have received an average rating of "Buy" from the sixteen analysts that are presently covering the firm, MarketBeat.com reports. One...
MarketBeat·20d ago
News Placeholder
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Analysts
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been given an average recommendation of "Buy" by the sixteen ratings firms that are currently covering the firm, MarketBeat...
MarketBeat·20d ago
News Placeholder
Marex Group plc Takes $3.67 Million Position in Denali Therapeutics Inc. $DNLI
Marex Group plc acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the second quarter, according to the company in its most recent disclosure with the...
MarketBeat·1mo ago
News Placeholder
Camber Capital Management LP Has $5.60 Million Position in Denali Therapeutics Inc. $DNLI
Camber Capital Management LP cut its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 68.0% in the second quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·1mo ago
News Placeholder
Wedbush Issues Pessimistic Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price
Wedbush lowered their target price on Denali Therapeutics from $31.00 to $30.00 and set an "outperform" rating on the stock in a research report on Thursday...
MarketBeat·1mo ago
News Placeholder
Denali Therapeutics (NASDAQ:DNLI) Shares Gap Down - Here's What Happened
Denali Therapeutics (NASDAQ:DNLI) Shares Gap Down - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Marshall Wace LLP Sells 783,172 Shares of Denali Therapeutics Inc. $DNLI
Marshall Wace LLP lessened its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 35.8% during the second quarter, according to the company in its most recent filing with...
MarketBeat·1mo ago
News Placeholder
BTIG Research Reiterates Buy Rating for Denali Therapeutics (NASDAQ:DNLI)
BTIG Research restated a "buy" rating and issued a $32.00 price objective on shares of Denali Therapeutics in a research note on Friday...
MarketBeat·1mo ago
<
1
2
...
>

Latest DNLI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.